BRAF V600E

BRAF codon 600 point mutation p.V600E detected by sequencing, PCR or mutation-specific immunohistochemistry; used as a predictive marker for BRAF/MEK inhibitor therapy across melanoma, thyroid, colorectal, lung and other cancers.

CI-BIO-00000018BRAF graph →NCIt C98342 Tumor-agnostic · 4 approval rows

Also calledp.V600E · BRAF V600E-mutant · c.1799T>A

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug + indication textRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Trametinib US FDA · May 29, 2013 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (24)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	37	31	6	—	1 / 21 / 6 / 8 / 1
Melanoma	31	29	2	—	0 / 19 / 2 / 10 / 0
Thyroid Gland Papillary Carcinoma	12	3	8

Derived

Drugs with predictive evidence (29)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	45	36	9	A	34 / 9	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +12
DabrafenibSmall Molecule	22	19	3	A	18 / 4	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
TrametinibSmall Molecule	20	19	1	A	18 / 0	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
CetuximabMonoclonal Antibody	12	6	6	A	6 / 5	Malignant Colorectal Neoplasm
PanitumumabMonoclonal Antibody	9	6	3	B	4 / 2	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	6	3	3	B	3 / 3	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	4	3	1	B	1 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
CobimetinibSmall Molecule	3	3	—	B	3 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
OxaliplatinSmall Molecule	2	—	2	B	0 / 2	Malignant Colorectal Neoplasm
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
SorafenibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
TovorafenibSmall Molecule	1	1	—	A	1 / 0	Childhood Low Grade Glioma
MEK Inhibitor RO4987655	1	—	1	B	—	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (92)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–92 of 92 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E27
Vemurafenib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5959 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	5	accepted	EID95 Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma. PMID 24583796 · Menzies et al., 2014 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	5
BRAF V600E + BRAF V600M1
Dabrafenib	Melanoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID73 A single 66-year old male patient with advanced melanoma thought to have concomitant BRAF V600E and V600M mutations responded rapidly to dabrafenib. His shoulder lesion reduced by 60% after 1 week of … (full text at CIViC) PMID 23031422 · Ponti et al., 2012 · Open in CIViC	civic
BRAF V600E + BRAF V600K2
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID93 This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC	civic
Vemurafenib	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1410 Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E (n=122) or V600K (n=10) mutation. Confirmed overall response rate was 53% (95% confidence interval [CI], 44 t… (full text at CIViC) PMID 22356324 · Sosman et al., 2012 · Open in CIViC	civic
BRAF V600E + EZH2 Y646FEZH2 BRAF1
JQEZ5	Melanoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID6952 Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma. PMID 27135738 · Souroullas et al., 2016 · Open in CIViC	civic
AKT1 E17K + BRAF V600EAKT1 BRAF1
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID707 A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF V600E + PTEN LossBRAF PTEN1
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID708 Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF V600E + NF1 LossBRAF NF11
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID90 In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors. PMID 24576830 · Nissan et al., 2014 · Open in CIViC	civic
BRAF V600E + KRAS G12DBRAF KRAS1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID3957 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + PIK3R2 N561DBRAF PIK3R21
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID4783 An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + PIK3CA OverexpressionBRAF PIK3CA1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID6275 An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expr… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF Amplification + BRAF V600E + BRAF V600K1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6262 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + KRAS MutationBRAF KRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6264 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (364)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Selumetinib	US FDA	—	KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )	approved	Sep 10, 2025	openfda
Selumetinib	US FDA	—	Efficacy supplement 2025-09-10 (see label)	approved	Sep 10, 2025	openfda
Selumetinib	US FDA	—	Efficacy supplement 2024-01-24 (see label)	approved	Jan 24, 2024	openfda
Selumetinib

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (473)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 247 recruiting · 84 active phase 3 · 2,296 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 201–250 of 473 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07281768	Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer	recruiting	Phase 2	66	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Jul 21, 2026	clinicaltrials
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	active not recruiting	Phase 1	750	Eli Lilly and CompanyINDUSTRY	8	Jul 20, 2026	clinicaltrials
NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	Phase 2	50	National Cancer Institute (NCI)NIH	1	Jul 17, 2026	clinicaltrials
NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	Phase 2	4	National Cancer Institute (NCI)NIH	1	Jul 17, 2026	clinicaltrials
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	Phase 2	59	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	Phase 1 / Phase 2	37	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT04188145	A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer(BEVAMAINT)	active not recruiting	Phase 3	400	Centre Hospitalier Universitaire DijonOTHER	1	Jul 16, 2026	clinicaltrials
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	recruiting	Phase 2	270	Corcept TherapeuticsINDUSTRY	8	Jul 16, 2026	clinicaltrials
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	recruiting	Phase 2	144	Ono Pharmaceutical Co., Ltd.INDUSTRY	6	Jul 16, 2026	clinicaltrials
NCT03148418	A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)	active not recruiting	Phase 3	382	Hoffmann-La RocheINDUSTRY	32	Jul 10, 2026	clinicaltrials
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	recruiting	Phase 1 / Phase 2	85	Mayo ClinicOTHER	1	Jul 10, 2026	clinicaltrials
NCT06109779	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)	active not recruiting	Phase 3	760	AstraZenecaINDUSTRY	21	Jul 10, 2026	clinicaltrials
NCT07637851	Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar)	not yet recruiting	Phase 1 / Phase 2	43	ARCAGY/ GINECO GROUPOTHER	1	Jul 10, 2026	clinicaltrials
NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	active not recruiting	Early Phase 1	13	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 7, 2026	clinicaltrials
NCT03737643	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O)	active not recruiting	Phase 3	1,407	AstraZenecaINDUSTRY	20	Jul 7, 2026	clinicaltrials
NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	Phase 2	16	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 6, 2026	clinicaltrials
NCT07300150	A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors	recruiting	Phase 1	210	PAQ Therapeutics, Inc.INDUSTRY	2	Jul 6, 2026	clinicaltrials
NCT04576117	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	active not recruiting	Phase 3	300	National Cancer Institute (NCI)NIH	2	Jul 2, 2026	clinicaltrials
NCT04626635	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers(COMBINE-EGFR-1)	active not recruiting	Phase 1 / Phase 2	548	Regeneron PharmaceuticalsINDUSTRY	7	Jul 2, 2026	clinicaltrials
NCT06819007	Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01)	recruiting	Phase 3	582	Daiichi SankyoINDUSTRY	25	Jul 2, 2026	clinicaltrials
NCT06839105	A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies	recruiting	Phase 1	214	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Jul 2, 2026	clinicaltrials
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	active not recruiting	Phase 1	5	City of Hope Medical CenterOTHER	1	Jul 1, 2026	clinicaltrials
NCT04835805	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.	active not recruiting	Phase 1	65	Genentech, Inc.INDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT07079631	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer	recruiting	Phase 1 / Phase 2	482	BioNTech SEINDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT06412198	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	recruiting	Phase 1 / Phase 2	31	M.D. Anderson Cancer CenterOTHER	1	Jun 26, 2026	clinicaltrials
NCT03175432	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	active not recruiting	Phase 2	29	M.D. Anderson Cancer CenterOTHER	1	Jun 25, 2026	clinicaltrials
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	active not recruiting	Phase 1	138	Toray Industries, IncINDUSTRY	2	Jun 23, 2026	clinicaltrials
NCT05005403	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	recruiting	Phase 1	694	AbbVieINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT05584670	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	542	SanofiINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT06813079	Using Tumor Models to Determine Treatments	recruiting	Phase 2	25	University Health Network, TorontoOTHER	1	Jun 23, 2026	clinicaltrials
NCT07662031	Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer	not yet recruiting	Phase 2	25	Washington University School of MedicineOTHER	1	Jun 23, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Jun 22, 2026	clinicaltrials
NCT05843188	Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer	active not recruiting	Phase 2	155	University Health Network, TorontoOTHER	1	Jun 22, 2026	clinicaltrials
NCT04722575	Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma(NEO-TIM)	active not recruiting	Phase 2	95	Fondazione Melanoma OnlusOTHER	1	Jun 18, 2026	clinicaltrials
NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	Phase 1	24	University of California, San FranciscoOTHER	1	Jun 18, 2026	clinicaltrials
NCT05999812	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	active not recruiting	Phase 2	22	University of Texas Southwestern Medical CenterOTHER	1	Jun 17, 2026	clinicaltrials
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	active not recruiting	Phase 2	110	Cardiff OncologyINDUSTRY	1	Jun 16, 2026	clinicaltrials
NCT06642844	Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL)	recruiting	Phase 3	244	University Hospital, ToursOTHER	1	Jun 16, 2026	clinicaltrials
NCT02671435	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors	active not recruiting	Phase 1 / Phase 2	383	MedImmune LLCINDUSTRY	11	Jun 15, 2026	clinicaltrials
NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03)	active not recruiting	Phase 1 / Phase 2	74	Novartis PharmaceuticalsINDUSTRY	8	Jun 15, 2026	clinicaltrials
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	active not recruiting	Phase 2	48	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials
NCT04324112	Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL	active not recruiting	Phase 2	28	National Cancer Institute (NCI)NIH	1	Jun 12, 2026	clinicaltrials
NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	Phase 2	44	National Cancer Institute (NCI)NIH	1	Jun 12, 2026	clinicaltrials
NCT04616183	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	46	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials
NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	Phase 2	52	M.D. Anderson Cancer CenterOTHER	1	Jun 11, 2026	clinicaltrials
NCT04017650	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	38	M.D. Anderson Cancer CenterOTHER	1	Jun 11, 2026	clinicaltrials
NCT07318389	ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer	not yet recruiting	Early Phase 1	100	M.D. Anderson Cancer CenterOTHER	1	Jun 11, 2026	clinicaltrials
NCT04587128	Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC	active not recruiting	Phase 2	34	University of Wisconsin, MadisonOTHER	1	Jun 10, 2026	clinicaltrials
NCT06835569	A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations	recruiting	Phase 1	448	Alterome Therapeutics, Inc.INDUSTRY	1	Jun 10, 2026	clinicaltrials
NCT03839342	Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations(BEAVER)	active not recruiting	Phase 2	26	University Health Network, TorontoOTHER	1	Jun 8, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (24)

Drugs with predictive evidence (29)

Predictive evidence items (92)

Approvals mentioning the linked drugs (364)

Active trials (473)

Linked publications (85)